en · de · es · fr · pt
tb-500-notes.peptides7250.com › Data › Tb-500 Identity And Naming Background — Research Overview

Tb-500 Identity And Naming Background — Research Overview

By Editorial Desk · published 2026-03-11 · last reviewed 2026-04-07 · Data

Everything below concerns Research peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.

Storage and Analytical Verification

Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Tb-500 at a glance

PropertyValueNotes
Name typeCommercial trade nameNot a systematic chemical identifier
Parent peptideThymosin beta-443-residue natural peptide
Common fragment sequenceLKKTETQMaps to part of the actin-binding region
Molecular size classRoughly 0.8-1.0 kDaDepends on exact fragment and terminal modification
Regulatory statusProhibited in sportGrouped with peptide hormones in many frameworks

Identification and Molecular Background

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

Related pages on this site

TB-500 Background and Identity

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Handling, Storage, and Analysis

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.

TB-500 Identity and Chemical Background

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Further detail

Using Mendeleev's nomenclature for unnamed and undiscovered elements, copernicium should be known as eka-mercury. In 1979, IUPAC published recommendations according to which the element was to be called ununbium (with the corresponding symbol of Uub), a systematic element name as a placeholder, until the element was discovered (and the discovery then confirmed) and a permanent name was decided on. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 112", with the symbol of E112, (112), or even simply 112. After acknowledging the GSI team's discovery, the IUPAC asked them to suggest a permanent name for element 112. On 14 July 2009, they proposed copernicium with the element symbol Cp, after Nicolaus Copernicus "to honor an outstanding scientist, who changed our view of the world". During the standard six-month discussion period among the scientific community about the naming, it was pointed out that the symbol Cp was previously associated with the name cassiopeium (cassiopium), now known as lutetium (Lu). Moreover, Cp is frequently used today to mean the cyclopentadienyl ligand (C5H5). Primarily because cassiopeium (Cp) was (until 1949) accepted by IUPAC as an alternative allowed name for lutetium, the IUPAC disallowed the use of Cp as a future symbol, prompting the GSI team to put forward the symbol Cn as an alternative.

== Plot == Joe Huff is an Alabama cop who has been suspended for excessive violence. After stopping a supermarket robbery, he is summoned by FBI agent Lance Dockery, who takes him to meet with special agent Frank Cunningham. Cunningham blackmails Joe by threatening to turn Joe's three-week suspension into six months without pay. Cunningham wants Joe to go undercover in Mississippi and infiltrate The Brotherhood, a white supremacist biker gang linked to the murders of government officials and suspected of dealing drugs to the mafia. The Brotherhood is led by Chains Cooper. Joe goes undercover as "John Stone". Tasked with killing a Bolivian man as his initiation, Joe enlists the FBI's help to fake the murder and is accepted into the Brotherhood. However, Chains' right-hand man, Ice Hensley, does not trust Joe and tries to expose him, leading to Ice's death in a high-speed motorcycle chase. Joe learns that the Brotherhood's goal is to eliminate Brent "The Whip" Whipperton, a district attorney running for Governor of Mississippi, who has promised to crack down on crime. They plan to use stolen military weapons to storm the Supreme Court at the Mississippi State Capitol, where Trouble Owens, one of their own, is on trial for murder, to assassinate Whipperton and the judges. When Chains' girlfriend, Nancy, accidentally learns about Joe's identity, he offers her immunity if she cooperates with the FBI. Though reluctant at first, Nancy accepts his offer, but they are discovered when the Bolivian man Joe had supposedly killed as an initiation returns.

== Structure == TRAIL shows homology to other members of the tumor necrosis factor superfamily. It is composed of 281 amino acids and has characteristics of a type II transmembrane protein. The N-terminal cytoplasmic domain is not conserved across family members, however, the C-terminal extracellular domain is conserved and can be proteolytically cleaved from the cell surface. TRAIL forms a homotrimer that binds three receptor molecules.

Sources: en.wikipedia.org

Background from the literature

A single-molecule electrically operated motor made from a single molecule of n-butyl methyl sulfide (C5H12S) has been reported. The molecule is adsorbed onto a copper (111) single-crystal piece by chemisorption.

Charlotte, with intermediate stops including Cary, Durham, Burlington and Greensboro, North Carolina. New York City, with intermediate stops including Richmond, VA; Washington, D.C.; Baltimore, MD; and Philadelphia, PA. Miami, with intermediate stops including Columbia, SC, and Savannah, GA; as well as Jacksonville, Orlando and Tampa, FL. Chicago, with intermediate stops including Pittsburgh, PA, Cleveland, OH, and Toledo, OH.

==== MeSH D06.472.445 – invertebrate hormones ==== MeSH D06.472.445.573 – insect hormones MeSH D06.472.445.573.271 – ecdysteroids MeSH D06.472.445.573.271.500 – ecdysone MeSH D06.472.445.573.271.750 – ecdysterone MeSH D06.472.445.573.666 – juvenile hormones MeSH D06.472.445.573.666.170 – diflubenzuron MeSH D06.472.445.573.666.500 – methoprene

Sources: en.wikipedia.org

Reference notes

=== Systems Pharmacology === Systems Pharmacology models integrate pharmacokinetics, pharmacodynamics, and systems biology to provide a comprehensive understanding of drug effects. By considering the intricate interplay between drugs, biological systems, and disease pathways, these models contribute to a holistic approach to drug development and personalized medicine.

The first large-scale application of strontium was in the production of sugar from sugar beet. Although a crystallisation process using strontium hydroxide was patented by Augustin-Pierre Dubrunfaut in 1849 the large scale introduction came with the improvement of the process in the early 1870s. The German sugar industry used the process well into the 20th century. Before World War I the beet sugar industry used 100,000 to 150,000 tons of strontium hydroxide for this process per year. The strontium hydroxide was recycled in the process, but the demand to substitute losses during production was high enough to create a significant demand initiating mining of strontianite in the Münsterland. The mining of strontianite in Germany ended when mining of the celestine deposits in Gloucestershire started. These mines supplied most of the world strontium supply from 1884 to 1941. Although the celestine deposits in the Granada basin were known for some time the large scale mining did not start before the 1950s. During atmospheric nuclear weapons testing, it was observed that strontium-90 is one of the nuclear fission products with a relatively high yield. The similarity to calcium and the chance that the strontium-90 might become enriched in bones made research on the metabolism of strontium an important topic.

Histopathology (compound of three Greek words: ἱστός histos 'tissue', πάθος pathos 'suffering', and -λογία -logia 'study of') is the microscopic examination of tissue in order to study the manifestations of disease. Specifically, in clinical medicine, histopathology refers to the examination of a biopsy or surgical specimen by a pathologist, after the specimen has been processed and histological sections have been placed onto glass slides. In contrast, cytopathology examines free cells or tissue micro-fragments (as "cell blocks").

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

What does research on the fragment actually measure?

Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.

Why does the name cause confusion?

Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.

How is the powder stored before use?

Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.

Network